Mr. Truesdale has over 15 years of sales management experience in the design, development and qualification of temperature controlled packaging solutions. He brings to the position an extensive background and understanding of supply chain management and related industry standards with an emphasis on achieving the successful distribution of temperature sensitive products within the cold chain. Prior to joining AcuTemp, Bruce held sales and executive positions at packaging companies, Tech Pak Solutions, Inc. and Chick Companies, Inc., and most recently held the position of Vice President of Sales and Marketing at RT Cotter and Associates, Inc., a consulting group providing safety and accreditation services to the healthcare industry.
“We are very please to have Bruce join the AcuTemp sales team,” said Vince Reidy, Vice President of Strategic Business Development for AcuTemp. “Bruce's considerable understanding of package development and cold chain management in the biomedical, pharmaceutical and medical device sectors will be of great value to our life sciences customers as AcuTemp continues to strengthen its position as a preferred provider of performance solutions for shipping temperature sensitive products.”
Mr. Truesdale will focus his business development efforts on presenting AcuTemp temperature controlled passive boxes and active container solutions to pharmaceutical and biotech companies in the Eastern United States. The company's passive shipper capabilities include a line of ISTA qualified boxes as well as the ability to design and manufacture custom solutions tested to a customer-specified protocol. All AcuTemp passive solutions are eligible for participation in the company's sustainability REPAQ™ program - a reusable program that retests the thermal integrity of each passive shipper before reuse.
Mr. Truesdale earned an undergraduate degree from Babson College, Babson Park, MA; and he holds a MBA degree from Northeastern University, Boston, MA. He is also a member of the Institute of Packaging Professionals (IOPP) and the Parenteral Drug Association (PDA) Pharmaceutical Cold Chain Interest Group.